The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells

[1]  S. Singer,et al.  ACTR-28. FINAL RESULTS FROM THE DOSE-ESCALATION STAGE OF A PHASE 1/2 TRIAL OF TPI 287, A BRAIN PENETRABLE MICROTUBULE INHIBITOR, PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA , 2017 .

[2]  T. Mitchison,et al.  Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic. , 2017, Endocrine-related cancer.

[3]  K. Nackaerts,et al.  Randomized phase 2 study of investigational aurora A kinase (AAK) inhibitor alisertib (MLN8237) + paclitaxel (P) vs placebo + P as second line therapy for small-cell lung cancer (SCLC) , 2016 .

[4]  K. Venkatakrishnan,et al.  Open‐label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors , 2016, Cancer.

[5]  A. Lujambio.  To clear, or not to clear (senescent cells)? That is the question , 2016, BioEssays : news and reviews in molecular, cellular and developmental biology.

[6]  D. Eslin,et al.  A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma , 2016, Pediatric blood & cancer.

[7]  F. Khuri,et al.  Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer , 2015, Oncotarget.

[8]  C. Wetmore,et al.  Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children. , 2015, Neuro-oncology.

[9]  Mickael Guedj,et al.  Analysis of drug combinations: current methodological landscape , 2015, Pharmacology research & perspectives.

[10]  W. Duan,et al.  Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells , 2015, Drug design, development and therapy.

[11]  M. Aghi,et al.  Molecularly targeted therapies for recurrent glioblastoma: current and future targets. , 2014, Neurosurgical focus.

[12]  N. Lehman,et al.  Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma. , 2014, Cancer research.

[13]  A. Nogales,et al.  Taxanes with high potency inducing tubulin assembly overcome tumoural cell resistances. , 2014, Bioorganic & medicinal chemistry.

[14]  N. Gomez-roman,et al.  Differential sensitivity of Glioma stem cells to Aurora kinase A inhibitors: Implications for stem cell mitosis and centrosome dynamics , 2014, Stem cell research.

[15]  Stephen L. Brown,et al.  The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation , 2014, Cancer Chemotherapy and Pharmacology.

[16]  S. Steinberg,et al.  TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells , 2012, Molecular Cancer Therapeutics.

[17]  T. Mikkelsen,et al.  Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas , 2012, Cell cycle.

[18]  S. Leenstra,et al.  Recent advances in the molecular understanding of glioblastoma , 2012, Journal of Neuro-Oncology.

[19]  Rachel E. Gershman,et al.  Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays , 2011, Clinical Cancer Research.

[20]  P. Lavia,et al.  Aurora-A inactivation causes mitotic spindle pole fragmentation by unbalancing microtubule-generated forces , 2011, Molecular Cancer.

[21]  Y. Iwase,et al.  3-Cyano-6-(5-methyl-3-pyrazoloamino)pyridines: selective Aurora A kinase inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[22]  A. Mcdonald,et al.  MLN8054, an Inhibitor of Aurora A Kinase, Induces Senescence in Human Tumor Cells Both In vitro and In vivo , 2010, Molecular Cancer Research.

[23]  Anindya Dutta,et al.  p21 in cancer: intricate networks and multiple activities , 2009, Nature Reviews Cancer.

[24]  A. Chakravarty,et al.  The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents , 2009, Cell cycle.

[25]  F. Gergely,et al.  Aurora-A: the maker and breaker of spindle poles , 2007, Journal of Cell Science.

[26]  Wei Chen,et al.  Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase , 2007, Proceedings of the National Academy of Sciences.

[27]  Eiji Kohmura,et al.  Aurora-A Kinase Maintains the Fidelity of Early and Late Mitotic Events in HeLa Cells* , 2003, Journal of Biological Chemistry.

[28]  W. B. Derry,et al.  Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. , 1996, Cancer research.

[29]  W. Greco,et al.  The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.

[30]  M. Taphoorn,et al.  Paclitaxel (Taxol) concentrations in brain tumor tissue. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  M. Jordan,et al.  Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Loewe.  The problem of synergism and antagonism of combined drugs. , 1953, Arzneimittel-Forschung.

[33]  C. I. Bliss.  THE TOXICITY OF POISONS APPLIED JOINTLY1 , 1939 .

[34]  S. Choi,et al.  Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients , 2013, Cancer Chemotherapy and Pharmacology.

[35]  Y. Sunada,et al.  Mechanism of taxane neurotoxicity , 2004, Breast cancer.

[36]  E. Rowinsky.  The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. , 1997, Annual review of medicine.

[37]  J. Manfredi,et al.  Taxol: an antimitotic agent with a new mechanism of action. , 1984, Pharmacology & therapeutics.

[38]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.